Project description
A novel drug design approach against cancer targets
Most small-molecule drugs against proteins usually target a regulatory moiety or the enzymatic active centre. However, there are molecular targets where this strategy cannot be implemented. The EU-funded E3glueRBP project proposes to address this issue through small molecules that induce interaction between two proteins and cause degradation of the disease-associated target. The team will develop a platform that utilises computational and biochemical methods to predict such protein domains and design appropriate molecular inhibitors. Project results will advance the field of cancer drug development and expand current therapeutic opportunities.
Objective
Conventional therapeutic strategy entails developing small molecules to occupy enzymatically active or regulatory pockets of the target protein, and further inhibit its biochemical activity. However, many disease-relevant proteins, such as RAS, MYC, or b-catenin, lack manageable druggable cavities. Bernardes and colleagues have raised a novel concept to overcome this limitation, named “molecular glues”, in which small molecules induce de-novo interactions between two proteins to modulate protein function. Molecular glues appeared as an elegant tool for targeted protein degradation, allowing simultaneous recruitment of a ubiquitin E3 ligase and the protein to be ubiquitinated. Notably, the potent anti-cancer drugs thalidomide, lenalidomide and pomalidomide (known as IMiDs for immuno-modulatory drugs), are the most prominent example of such E3-hijacking molecular glues, that exert their therapeutic effects through induced degradation of key efficacy targets. Building on these promising observations, herein I propose a designed platform that can rationally identify synthetic chemical matter to induce selective protein dimerization and induce disease-relevant protein ubiquitination and degradation – using ubiquitin E3 ligase and RNA binding protein IGF2BP1 as a proof-of-concept in ovarian carcinoma cells. The identification of complementary interfaces for drug-induced interactions will be achieved by computational prediction, protein-protein interaction assays, and a set of novel biochemical assays, together with high-throughput screening and structure-informed chemical optimization. This proposal will deliver a multi-layered technology to successfully design and validate novel molecular glues in a rational and generalizable way, to revolutionize current inhibitor-centric paradigms in cancer drug development and pharmacology. The strategy can be further transposed to other protein classes in different cancer types, and open an array of new therapeutic opportunities.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- natural sciences biological sciences biochemistry biomolecules proteins proteomics
- medical and health sciences clinical medicine oncology
- natural sciences biological sciences genetics RNA
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.4. - SPREADING EXCELLENCE AND WIDENING PARTICIPATION
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-WF-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1649 028 Lisboa
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.